Eli Lilly said Friday it plans to ask the FDA for a label expansion of its immunology drug Olumiant in adolescents with alopecia after successful long-term data. At one year of follow-up, Lilly said 54 …

Remix Therapeutics, which is developing a new way to shut down the expression of cancer-causing genes, has seen the first signs of success in a rare salivary gland cancer. The company is developing small-molecule drugs …

Merus on Friday released new data for its drug petosemtamab in multiple lines of colorectal cancer, potentially giving it additional utility beyond its primary focus of head and neck tumors. In first-line colorectal cancer, petosemtamab …

Zai Lab on Friday reported updated early-stage data for its closely-watched ADC candidate that could compete with Amgen’s Imdelltra. Both drugs target the DLL3 protein and are designed to treat extensive-stage small cell lung cancer …

Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.

In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Katie Morris, now a senior account executive and scientific liaison at Entente Network, discussed the transition from research to marketing and shared her personal formula for success.

AstraZeneca and Organon have breached the UK pharma industry’s code of practice with promotions for an asthma drug and a contraceptive implant.

Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their pediatricians to adult care, for which they’re often unprepared.

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

→ In addition to the hullabaloo surrounding its board of directors, Novo Nordisk has filled a crucial role as it wrestles with President Donald Trump’s drug pricing demands. Greg Miley